Oral glutamine supplementation in prevention of radiotherapy-induced esophagitis in advanced non-small cell lung cancer patients
演題番号 : P25-4
1:Far Eastern Memorial Hospital, New Taipei City, Taiwan・Internal Medicine・Chest Medicine
Complications related to concurrent chemoradiotherapy (CCRT) such as acute radiation-induced esophagitis (ARIE) may cause significant morbidity and unplanned treatment delays in patients with advanced non-small cell lung cancer (NSCLC). We designed a prospective randomized study to assess the impact of Glutamine supplementation in preventing CCRT-induced toxicities of advanced NSCLC patients.
Thirty patients diagnosed with NSCLC were included to the study. Fifteen patients (50%) received prophylactic powdered GLN orally at a dose of 10g/8h. The prescribed radiation dose to the planning target volume was 30 Gy in 2-Gy fractions. The endpoints were radiation-induced esophagitis, mucositis and body weight loss.
At a median follow-up of 18.4 months (range 8.4-28.2), all patients tolerated GLN well. Administration of GLN was associated with a decrease in the incidence of grade 2 or 3 ARIE (6.7% vs. 53.4% for Gln+ vs. Gln-; p=0.004). GLN supplementation appeared to significantly delay ARIE onset for 5 days (18 days vs.12 days; p=0.027) and reduced incidence of weight loss (20% vs. 73.3%; p=0.01).
Our study suggests a beneficial effect of oral glutamine supplementation for the prevention from radiation-induced injury and body weight loss in advanced NSCLC patients who receiving CCRT.